World’s IT Giants Target Japanese Pharmaceutical Companies In Genome Information Sharing
This article was originally published in PharmAsia News
Amid major Japanese pharmaceutical companies eager to expand into overseas markets a, developing new drugs has been a top priority. In order to speed up new drug development, companies are looking for systems that allow real-time sharing of genome analysis and research information. Several IT giants market new drug development support systems specifically targeting Japanese pharmaceutical companies. British Telecom last month announced it has developed a system supporting Japanese drug makers expanding overseas. American company Cognizant partners with CTC Laboratory Systems, a subsidiary of Itochu Techno-Solutions, and will provide CTC customers with genome analysis services. IBM Japan also plans to expand sales of its system that electronically uploads and shares research notes among pharmaceutical researchers. (Click here for more - Japanese language
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.